Product Description
Lixisenatide is a 44-amino acid peptide. Like exenatide, it is based on exendin-4 with a modification at the C-terminus—a deletion of a proline residue and the addition of six lysine residues.15 It is amidated at the C-terminal amino acid (position 44) (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642155/)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Paresis | Gastroparesis | Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes
Known Adverse Events: Dizziness | Headache | Hypoglycemia | Diarrhea
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Hong Kong, Korea, Malaysia, South Korea, Taiwan
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 2: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LixiPark | P2 |
Completed |
Parkinson's Disease |
2021-04-15 |
|
| Lixilan-O-AP | P3 |
Completed |
Type 2 Diabetes |
2021-03-01 |
78% |
| CTR20181388 | P3 |
Completed |
Type 2 Diabetes |
2021-03-01 |